Literature DB >> 12239593

Significance of brain natriuretic peptides in patients on continuous ambulatory peritoneal dialysis.

Tatuya Nakatani1, Toshihide Naganuma, Chikayoshi Masuda, Junji Uchida, Takeshi Sugimura, Kazunobu Sugimura.   

Abstract

It is well known that plasma brain natriuretic peptide (BNP) concentration is elevated in cardiovascular diseases such as congestive heart failure. However, although it has been reported to increase in hemodialysis (HD) patients, little is known about plasma BNP in patients undergoing continuous ambulatory peritoneal dialysis (CAPD). Plasma BNP concentrations were measured and compared among CAPD patients (n=32), HD patients (n=63) and healthy volunteers (n=14) as well as those patients without cardiovascular disease. In addition, the correlation between plasma BNP concentration and parameters of echocardiography was examined. Plasma BNP concentration was significantly higher in CAPD patients without cardiovascular disease (n=23) than in healthy volunteers (n=14) (62.1+/-60.6 pg/ml versus 9.7+/-9.7 pg/ml, mean +/- SD, P<0.0001). Furthermore, it had a positive correlation with LVMI (CAPD: r=0.37, P=0.0354; HD: r=0.49, P<0.0001) but a negative correlation with LVEF (CAPD: r=-0.39, P=0.0277; HD: r=-0.40, P=0.0010) in both CAPD and HD patients. When all patients were compared, plasma BNP concentration was significantly lower in CAPD patients (n=32) than in HD patients (n=63) (114.8+/-142.7 pg/ml versus 296.8+/-430.4 pg/ml, P<0.0001). When those patients without cardiovascular disease was compared, it was also significantly lower in CAPD patients (n=23) than in HD patients (n=40) (62.1+/-60.6 pg/ml versus 151.8+/-102.2 pg/ml, P<0.0001). In conclusion, plasma BNP concentration was elevated in CAPD patients and correlated with LVMI and LVEF, suggesting that plasma BNP in CAPD patients may be associated with left ventricular hypertrophy (LVH) and left ventricular systolic dysfunction. In addition, plasma BNP concentration was significantly lower in CAPD patients than in HD patients, suggesting that cardiac load in CAPD patients may be lower than that of HD patients.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12239593

Source DB:  PubMed          Journal:  Int J Mol Med        ISSN: 1107-3756            Impact factor:   4.101


  6 in total

Review 1.  Assessing cardiovascular risk in children with chronic kidney disease. B-type natriuretic peptide: a potential new marker.

Authors:  Gema Ariceta; Ellen R Brooks; Craig B Langman
Journal:  Pediatr Nephrol       Date:  2005-08-05       Impact factor: 3.714

2.  B-type natriuretic peptides strongly predict mortality in patients who are treated with long-term dialysis.

Authors:  Matthew A Roberts; Piyush M Srivastava; Neil Macmillan; David L Hare; Sujiva Ratnaike; Ken Sikaris; Francesco L Ierino
Journal:  Clin J Am Soc Nephrol       Date:  2008-05-01       Impact factor: 8.237

3.  Brain natriuretic peptide and P wave duration in dialysis patients.

Authors:  M Cagatay Taskapan; Soner Senel; Ozkan Ulutas; Yuksel Aksoy; Ibrahim Sahin; Feridun Kosar; Hulya Taskapan
Journal:  Int Urol Nephrol       Date:  2007-04-25       Impact factor: 2.370

4.  Predictive value of brain natriuretic peptides in patients on peritoneal dialysis: results from the ADEMEX trial.

Authors:  Ramon Paniagua; Dante Amato; Salim Mujais; Edward Vonesh; Alfonso Ramos; Ricardo Correa-Rotter; Walter H Horl
Journal:  Clin J Am Soc Nephrol       Date:  2008-01-16       Impact factor: 8.237

5.  Brain natriuretic peptide levels have diagnostic and prognostic capability for cardio-renal syndrome type 4 in intensive care unit patients.

Authors:  Sunghoon Park; Goo-Yeong Cho; Sung Gyun Kim; Yong Il Hwang; Hye-Ryun Kang; Seung Hun Jang; Dong-Gyu Kim; Young Rim Song; Young-A Bae; Ki-Suck Jung
Journal:  Crit Care       Date:  2009-05-15       Impact factor: 9.097

6.  The prognostic value of estimated glomerular filtration rate, amino-terminal portion of the pro-hormone B-type natriuretic peptide and parameters of cardiopulmonary exercise testing in patients with chronic heart failure.

Authors:  Hein J Verberne; Aukje van der Spank; Paul Bresser; G Aernout Somsen
Journal:  Heart Int       Date:  2012-06-19
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.